𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety risks with gadolinium-based contrast agents

✍ Scribed by Louis Marzella; Melanie Blank; Kate Gelperin; Rosemary Johann-Liang

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
35 KB
Volume
26
Category
Article
ISSN
1053-1807

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Response to: Safety risks with gadoliniu
Response to: Safety risks with gadolinium-based contrast agents
✍ Honglei Zhang; Jeffrey H. Maki; Martin R. Prince πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 29 KB

We are grateful to Drs. Marzella, Blank, Gelperin, and Johann-Liang of the U.S. Food and Drug Administration for providing a timely update/reminder on the evolving safety concerns related to gadolinium and especially to Gadodiamide's association with nephrogenic systemic fibrosis (NSF) as well as th

Biodistribution of gadolinium-based cont
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition
✍ Silvio Aime; Peter Caravan πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 270 KB

## Abstract The biodistribution of approved gadolinium (Gd)‐based contrast agents (GBCAs) is reviewed. After intravenous injection GBCAs distribute in the blood and the extracellular space and transiently through the excretory organs. Preclinical animal studies and the available clinical literature

Biochemical safety profiles of gadoliniu
Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis
✍ Hale Ersoy; Frank J. Rybicki πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 100 KB

## Abstract Gadolinium (Gd)‐based paramagnetic contrast agents are relatively safe when used in clinically recommended doses. However, with the rapidly expanding body of literature linking Gd‐based paramagnetic contrast agents and nephrogenic systemic fibrosis (NSF), awareness of the potential side

Safety of gadolinium-based contrast mate
Safety of gadolinium-based contrast material in sickle cell disease
✍ Jonathan R. Dillman; James H. Ellis; Richard H. Cohan; Elaine M. Caoili; Hero K. πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 69 KB

## Abstract ## Purpose: To assess the safety of intravenously administered gadolinium‐based contrast material in sickle cell disease (SCD) patients. ## Materials and Methods: All pediatric and adult SCD patients evaluated by magnetic resonance imaging (MRI) at our institution between January 199

Gadolinium-based contrast agents and NSF
Gadolinium-based contrast agents and NSF: Evidence from animal experience
✍ Martin A. Sieber; Thomas Steger-Hartmann; Philipp Lengsfeld; Hubertus Pietsch πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 927 KB

## Abstract Nephrogenic systemic fibrosis (NSF) is a potentially severe systemic disease typically characterized by fibrosis of the skin and connective tissues. The etiology of NSF is still unknown but is likely to be multifactorial. Specific triggers under scientific evaluation have included surge